Related Experiment Video
Updated: May 9, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Obesity and atrial fibrillation.
1Department of Medicine, University of Adelaide, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Summary
Obesity is a primary driver of the growing epidemic of atrial fibrillation (AF), impacting heart function and increasing mortality. Understanding these links can improve AF treatment outcomes.
Area of Science:
- Cardiology
- Metabolic Disease Research
Background:
- Atrial fibrillation (AF) presents a significant and growing public health challenge with substantial economic and mortality impacts.
- While population aging contributes, obesity and its related cardiometabolic conditions are increasingly recognized as the principal drivers of the AF epidemic.
Observation:
- Obesity-associated factors like hypertension, vascular disease, obstructive sleep apnea, and pericardial fat contribute to atrial electro-structural dysfunction.
- Insulin resistance and associated metabolic abnormalities promote structural and functional changes in the atria, leading to AF.
Findings:
- The review synthesizes evidence linking obesity to atrial electromechanical dysfunction.
- Mechanistic insights into pathways like atrial fibrosis are emerging, offering potential for targeted pharmacotherapy.
Implications:
- Understanding obesity's role in AF pathophysiology can refine therapeutic strategies and improve patient outcomes.
- Further research into these mechanisms may reveal novel management approaches and investigative avenues for AF.
Related Concept Videos
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...